10/31/14 DEPO 15.40 Depomed Inc $DEPO Hit a 52 wee
Post# of 88
Posted On: 11/01/2014 11:58:19 PM
10/31/14 DEPO 15.40 Depomed Inc $DEPO Hit a 52 week high of 16.00 Closing the day 10/31/14 at 15.40 +0.06 +0.39% With a day low of 15.21 and a total volume of 1,166,800.
DEPO Recent Posts: http://investorshangout.com/Depomed-DEPO-53892/
DEPO Depomed Inc Recent Headline News
23.7% Return Seen to Date on SmarTrend Depomed Call (DEPO)
Comtex SmarTrend(R) - Thu Oct 30, 9:18AM CDT
SmarTrend identified an Uptrend for Depomed (NASDAQ
EPO) on August 11th, 2014 at $12.34. In approximately 3 months, Depomed has returned 23.66% as of today's recent price of $15.26.
DEPO: 15.40 (+0.06)
High-growth Pharmaceutical Company Drives More Efficient Reviews with Veeva Vault PromoMats
Business Wire - Tue Oct 28, 6:03AM CDT
Depomed, Inc. has streamlined its promotional material review process and increased efficiency by replacing its Excel-based system with Vault PromoMats, Veeva Systems' promotional materials management solution. Bringing all parties together in the cloud for better collaboration, Vault PromoMats speeds the review and approval of promotional materials. Enabling Depomed to reduce its number of face-to-face medical, legal, and regulatory (MLR) reviews, Vault has provided the agility needed to keep up with the company's expanding portfolio of products.
VEEV: 29.78 (+0.99), DEPO: 15.40 (+0.06)
Global Postherpetic Neuralgia Clinical Trials Review, H2, 2014
M2 - Tue Oct 28, 5:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nkgchq/postherpetic) has announced the addition of the "Postherpetic Neuralgia Global Clinical Trials Review, H2, 2014" report to their offering. Postherpetic Neuralgia Global Clinical Trials Review, H2, 2014" provides data on the Postherpetic Neuralgia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Postherpetic Neuralgia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Postherpetic Neuralgia. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Clinical Trial Overview of Top Companies - Pfizer Inc. - NeurogesX, Inc. - Spinifex Pharmaceuticals Pty Limited - Merck & Co., Inc. - UCB S.A. - GlaxoSmithKline plc - Allergan, Inc. - Depomed, Inc. - Daiichi Sankyo Company, Limited - Astellas Pharma Inc. Clinical Trial Overview of Top Institutes / Government - University of California, San Francisco - Hopital Ambroise Pare - Shanghai Sixth People's Hospital - Xinhua Hospital - University of Wisconsin Madison - Nucleus Network - Shiraz University of Medical Sciences - George Washington University - Loma Linda University - University of Sao Paulo For more information visit http://www.researchandmarkets.com/research/nk...stherpetic
AGN: 190.06 (+0.62), PFE: 29.95 (+0.11), MRK: 57.94 (+0.63), DEPO: 15.40 (+0.06), GSK: 45.49 (+0.35)
Depomed To Report Third Quarter Fiscal Year 2014 Financial Results On Wednesday, November 5, 2014
PR Newswire - Mon Oct 27, 3:01PM CDT
Depomed, Inc. (NASDAQ: DEPO) today announced that it will release third quarter fiscal year 2014 financial results after the market closes on Wednesday, November 5, 2014. The Company will host a conference call beginning at 4:30 pm EST, 1:30 pm PST to discuss its results.
DEPO: 15.40 (+0.06)
Technical Report on Pharma Stocks - Auxilium Pharma, Perrigo, Endo Intl., Depomed, and Ampio Pharma
PR Newswire - Fri Oct 24, 7:45AM CDT
Investor-Edge has initiated coverage on the following equities: Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Perrigo Company PLC (NYSE: PRGO), Endo International PLC (NASDAQ: ENDP), Depomed Inc. (NASDAQ: DEPO), and Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, October 23, 2014, the NASDAQ Composite ended at 4,452.79, up 1.60%, the Dow Jones Industrial Average advanced 1.32%, to finish the day at 16,677.90, and the S&P 500 closed at 1,950.82, up 1.23%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 744.13, up 1.75%, with the index also advancing 3.88% in the previous three trading sessions. Register for your complimentary reports on these five stocks at:
ENDP: 66.92 (+0.63), PRGO: 161.45 (+0.12), AUXL: 32.17 (+0.29), DEPO: 15.40 (+0.06), AMPE: 3.88 (-0.02)
Depomed Shares Up 20.6% Since SmarTrend's Buy Recommendation (DEPO)
Comtex SmarTrend(R) - Wed Oct 22, 4:59PM CDT
SmarTrend identified an Uptrend for Depomed (NASDAQ EPO) on August 11th, 2014 at $12.34. In approximately 2 months, Depomed has returned 20.58% as of today's recent price of $14.88.
DEPO: 15.40 (+0.06)
Depomed Has Returned 14.4% Since SmarTrend Recommendation (DEPO)
Comtex SmarTrend(R) - Wed Oct 15, 11:20AM CDT
SmarTrend identified an Uptrend for Depomed (NASDAQ EPO) on August 11th, 2014 at $12.34. In approximately 2 months, Depomed has returned 14.42% as of today's recent price of $14.12.
DEPO: 15.40 (+0.06)
Depomed Up 16.6% Since SmarTrend Uptrend Call (DEPO)
Comtex SmarTrend(R) - Wed Oct 08, 9:58AM CDT
SmarTrend identified an Uptrend for Depomed (NASDAQ EPO) on August 11th, 2014 at $12.34. In approximately 2 months, Depomed has returned 16.61% as of today's recent price of $14.39.
DEPO: 15.40 (+0.06)
Depomed Has Returned 21.0% Since SmarTrend Recommendation (DEPO)
Comtex SmarTrend(R) - Wed Oct 01, 9:21AM CDT
SmarTrend identified an Uptrend for Depomed (NASDAQ EPO) on August 11th, 2014 at $12.34. In approximately 2 months, Depomed has returned 20.99% as of today's recent price of $14.93.
DEPO: 15.40 (+0.06)
Shares of DEPO Up 20.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Sep 23, 5:05PM CDT
SmarTrend identified an Uptrend for Depomed (NASDAQ EPO) on August 11th, 2014 at $12.34. In approximately 1 month, Depomed has returned 20.91% as of today's recent price of $14.92.
DEPO: 15.40 (+0.06)
Pharma Equities Technical Coverage - VIVUS, Auxilium Pharma, Depomed, Endo Intl., and Perrigo
PR Newswire - Wed Sep 10, 8:10AM CDT
On Tuesday, September 09, 2014, the NASDAQ Composite ended at 4,552.29, down 0.87%, the Dow Jones Industrial Average finished the day 0.57% lower at 17,013.87, and the S&P 500 closed at 1,988.44, down 0.65%. The losses were broad based as all the ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 739.32, down 0.31%, while the index has advanced 6.94% in the last three months. Investor-Edge has initiated coverage on the following equities: VIVUS Inc. (NASDAQ: VVUS), Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Depomed Inc. (NASDAQ: DEPO), Endo International PLC (NASDAQ: ENDP), and Perrigo Company PLC (NYSE: PRGO). Free research on these five companies can be accessed at:
ENDP: 66.92 (+0.63), PRGO: 161.45 (+0.12), AUXL: 32.17 (+0.29), VVUS: 3.39 (+0.03), DEPO: 15.40 (+0.06)
Depomed Summary Judgment Motion Granted in Suit against FDA Seeking Orphan Drug Exclusivity for Gralise® (Gabapentin)
PR Newswire - Fri Sep 05, 1:34PM CDT
Depomed, Inc. (Nasdaq EPO) today announced that Judge Kentaji Brown Jackson of the federal district court for the District of Columbia has granted Depomed's motion for summary judgment in the company's lawsuit against the United States Food and Drug Administration seeking an order requiring the FDA to grant Gralise® (gabapentin) Orphan Drug exclusivity for the management of postherpetic neuralgia (PHN).
DEPO: 15.40 (+0.06)
Market Maker Surveillance Report. PFE, TWX, CSCO, MDT, DEPO, QQQ, Bearishly Biased Price Friction For Thursday, September 4th 2014
M2 - Fri Sep 05, 3:10AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4751 companies with "abnormal" market making, 1909 companies with positive Friction Factors and 3133 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bearish bias) in their stock prices. This means that there was more buying than selling in the stocks and their stock prices dropped. Pfizer Inc (NYSE
FE), TIME WARNER INC. (NYSE:TWX), CISCO SYSTEMS INCORPORATED (NASDAQ:CSCO), Medtronic Inc (NYSE:MDT), Depomed Inc (NASDAQ EPO), Powershares Qqq Trust Series 1 (NASDAQ:QQQ). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
QQQ: 101.40 (+1.38), MDT: 68.16 (+0.73), PFE: 29.95 (+0.11), DEPO: 15.40 (+0.06), CSCO: 24.47 (+0.39), TWX: 79.47 (-0.18)
Depomed Announces Pricing of Upsized $300 Million Convertible Senior Notes Due 2021
PR Newswire - Thu Sep 04, 6:00AM CDT
Depomed, Inc. (Nasdaq: DEPO) today announced that it has priced its registered offering of $300 million aggregate principal amount of Convertible Senior Notes due 2021 (the "Notes"
. The offering was upsized from the previously announced $230 million aggregate principal amount. The Notes will bear interest at a rate of 2.50% per year, payable semiannually on March 1 and September 1 of each year, beginning on March 1, 2015. Depomed, Inc. ("Depomed" has granted the underwriters in the offering a 30-day option to purchase up to an additional $45 million aggregate principal amount of the Notes. Morgan Stanley & Co. LLC and RBC Capital Markets, LLC are acting as joint book-running managers for the offering. The sale of the Notes is expected to close on September 9, 2014, subject to customary closing conditions.
DEPO: 15.40 (+0.06), MS: 34.95 (+0.43)
Depomed Set to Possibly Rebound After Yesterday's Selloff of 8.62%
Comtex SmarTrend(R) - Wed Sep 03, 5:45PM CDT
Depomed (NASDAQ EPO) traded in a range yesterday that spanned from a low of $13.77 to a high of $14.90. Yesterday, the shares fell 8.6%, which took the trading range below the 3-day low of $15.07 on volume of 4.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
DEPO: 15.40 (+0.06)
Nasdaq stocks posting largest percentage decreases
AP - Wed Sep 03, 5:14PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
HELE: 61.85 (+1.09), RESN: 6.00 (unch), DHRM: 4.53 (-0.18), PACB: 6.56 (-0.06), PHII: 42.82 (-0.18), CONN: 31.11 (-0.67), RPRX: 6.34 (-0.41), DEPO: 15.40 (+0.06), PHIIK: 44.74 (+0.22), HMSY: 23.23 (+0.84), SVA: 5.29 (-0.15), DGLY: 14.62 (-0.07)
Depomed Announces Offering of $230 Million Convertible Senior Notes Due 2021
PR Newswire - Tue Sep 02, 3:00PM CDT
Depomed, Inc. (Nasdaq: DEPO) today announced that it intends to offer, subject to market and other conditions, $230 million aggregate principal amount of Convertible Senior Notes due 2021 (the "Notes" . Depomed, Inc. ("Depomed" expects to grant the underwriters in the offering a 30-day option to purchase up to an additional $34.5 million aggregate principal amount of the Notes. Morgan Stanley & Co. LLC and RBC Capital Markets, LLC will act as joint book-running managers for the offering. Depomed intends to use the net proceeds of the offering for working capital and other general corporate purposes and potential acquisitions and strategic transactions. There are currently no agreements or understandings with respect to any such acquisition or strategic transaction.
DEPO: 15.40 (+0.06), MS: 34.95 (+0.43)
DEPO Recent Posts: http://investorshangout.com/Depomed-DEPO-53892/
DEPO Depomed Inc Recent Headline News
23.7% Return Seen to Date on SmarTrend Depomed Call (DEPO)
Comtex SmarTrend(R) - Thu Oct 30, 9:18AM CDT
SmarTrend identified an Uptrend for Depomed (NASDAQ
EPO) on August 11th, 2014 at $12.34. In approximately 3 months, Depomed has returned 23.66% as of today's recent price of $15.26. DEPO: 15.40 (+0.06)
High-growth Pharmaceutical Company Drives More Efficient Reviews with Veeva Vault PromoMats
Business Wire - Tue Oct 28, 6:03AM CDT
Depomed, Inc. has streamlined its promotional material review process and increased efficiency by replacing its Excel-based system with Vault PromoMats, Veeva Systems' promotional materials management solution. Bringing all parties together in the cloud for better collaboration, Vault PromoMats speeds the review and approval of promotional materials. Enabling Depomed to reduce its number of face-to-face medical, legal, and regulatory (MLR) reviews, Vault has provided the agility needed to keep up with the company's expanding portfolio of products.
VEEV: 29.78 (+0.99), DEPO: 15.40 (+0.06)
Global Postherpetic Neuralgia Clinical Trials Review, H2, 2014
M2 - Tue Oct 28, 5:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nkgchq/postherpetic) has announced the addition of the "Postherpetic Neuralgia Global Clinical Trials Review, H2, 2014" report to their offering. Postherpetic Neuralgia Global Clinical Trials Review, H2, 2014" provides data on the Postherpetic Neuralgia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Postherpetic Neuralgia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Postherpetic Neuralgia. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Clinical Trial Overview of Top Companies - Pfizer Inc. - NeurogesX, Inc. - Spinifex Pharmaceuticals Pty Limited - Merck & Co., Inc. - UCB S.A. - GlaxoSmithKline plc - Allergan, Inc. - Depomed, Inc. - Daiichi Sankyo Company, Limited - Astellas Pharma Inc. Clinical Trial Overview of Top Institutes / Government - University of California, San Francisco - Hopital Ambroise Pare - Shanghai Sixth People's Hospital - Xinhua Hospital - University of Wisconsin Madison - Nucleus Network - Shiraz University of Medical Sciences - George Washington University - Loma Linda University - University of Sao Paulo For more information visit http://www.researchandmarkets.com/research/nk...stherpetic
AGN: 190.06 (+0.62), PFE: 29.95 (+0.11), MRK: 57.94 (+0.63), DEPO: 15.40 (+0.06), GSK: 45.49 (+0.35)
Depomed To Report Third Quarter Fiscal Year 2014 Financial Results On Wednesday, November 5, 2014
PR Newswire - Mon Oct 27, 3:01PM CDT
Depomed, Inc. (NASDAQ: DEPO) today announced that it will release third quarter fiscal year 2014 financial results after the market closes on Wednesday, November 5, 2014. The Company will host a conference call beginning at 4:30 pm EST, 1:30 pm PST to discuss its results.
DEPO: 15.40 (+0.06)
Technical Report on Pharma Stocks - Auxilium Pharma, Perrigo, Endo Intl., Depomed, and Ampio Pharma
PR Newswire - Fri Oct 24, 7:45AM CDT
Investor-Edge has initiated coverage on the following equities: Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Perrigo Company PLC (NYSE: PRGO), Endo International PLC (NASDAQ: ENDP), Depomed Inc. (NASDAQ: DEPO), and Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, October 23, 2014, the NASDAQ Composite ended at 4,452.79, up 1.60%, the Dow Jones Industrial Average advanced 1.32%, to finish the day at 16,677.90, and the S&P 500 closed at 1,950.82, up 1.23%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 744.13, up 1.75%, with the index also advancing 3.88% in the previous three trading sessions. Register for your complimentary reports on these five stocks at:
ENDP: 66.92 (+0.63), PRGO: 161.45 (+0.12), AUXL: 32.17 (+0.29), DEPO: 15.40 (+0.06), AMPE: 3.88 (-0.02)
Depomed Shares Up 20.6% Since SmarTrend's Buy Recommendation (DEPO)
Comtex SmarTrend(R) - Wed Oct 22, 4:59PM CDT
SmarTrend identified an Uptrend for Depomed (NASDAQ
EPO) on August 11th, 2014 at $12.34. In approximately 2 months, Depomed has returned 20.58% as of today's recent price of $14.88. DEPO: 15.40 (+0.06)
Depomed Has Returned 14.4% Since SmarTrend Recommendation (DEPO)
Comtex SmarTrend(R) - Wed Oct 15, 11:20AM CDT
SmarTrend identified an Uptrend for Depomed (NASDAQ
EPO) on August 11th, 2014 at $12.34. In approximately 2 months, Depomed has returned 14.42% as of today's recent price of $14.12. DEPO: 15.40 (+0.06)
Depomed Up 16.6% Since SmarTrend Uptrend Call (DEPO)
Comtex SmarTrend(R) - Wed Oct 08, 9:58AM CDT
SmarTrend identified an Uptrend for Depomed (NASDAQ
EPO) on August 11th, 2014 at $12.34. In approximately 2 months, Depomed has returned 16.61% as of today's recent price of $14.39. DEPO: 15.40 (+0.06)
Depomed Has Returned 21.0% Since SmarTrend Recommendation (DEPO)
Comtex SmarTrend(R) - Wed Oct 01, 9:21AM CDT
SmarTrend identified an Uptrend for Depomed (NASDAQ
EPO) on August 11th, 2014 at $12.34. In approximately 2 months, Depomed has returned 20.99% as of today's recent price of $14.93. DEPO: 15.40 (+0.06)
Shares of DEPO Up 20.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Sep 23, 5:05PM CDT
SmarTrend identified an Uptrend for Depomed (NASDAQ
EPO) on August 11th, 2014 at $12.34. In approximately 1 month, Depomed has returned 20.91% as of today's recent price of $14.92. DEPO: 15.40 (+0.06)
Pharma Equities Technical Coverage - VIVUS, Auxilium Pharma, Depomed, Endo Intl., and Perrigo
PR Newswire - Wed Sep 10, 8:10AM CDT
On Tuesday, September 09, 2014, the NASDAQ Composite ended at 4,552.29, down 0.87%, the Dow Jones Industrial Average finished the day 0.57% lower at 17,013.87, and the S&P 500 closed at 1,988.44, down 0.65%. The losses were broad based as all the ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 739.32, down 0.31%, while the index has advanced 6.94% in the last three months. Investor-Edge has initiated coverage on the following equities: VIVUS Inc. (NASDAQ: VVUS), Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Depomed Inc. (NASDAQ: DEPO), Endo International PLC (NASDAQ: ENDP), and Perrigo Company PLC (NYSE: PRGO). Free research on these five companies can be accessed at:
ENDP: 66.92 (+0.63), PRGO: 161.45 (+0.12), AUXL: 32.17 (+0.29), VVUS: 3.39 (+0.03), DEPO: 15.40 (+0.06)
Depomed Summary Judgment Motion Granted in Suit against FDA Seeking Orphan Drug Exclusivity for Gralise® (Gabapentin)
PR Newswire - Fri Sep 05, 1:34PM CDT
Depomed, Inc. (Nasdaq
EPO) today announced that Judge Kentaji Brown Jackson of the federal district court for the District of Columbia has granted Depomed's motion for summary judgment in the company's lawsuit against the United States Food and Drug Administration seeking an order requiring the FDA to grant Gralise® (gabapentin) Orphan Drug exclusivity for the management of postherpetic neuralgia (PHN). DEPO: 15.40 (+0.06)
Market Maker Surveillance Report. PFE, TWX, CSCO, MDT, DEPO, QQQ, Bearishly Biased Price Friction For Thursday, September 4th 2014
M2 - Fri Sep 05, 3:10AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4751 companies with "abnormal" market making, 1909 companies with positive Friction Factors and 3133 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bearish bias) in their stock prices. This means that there was more buying than selling in the stocks and their stock prices dropped. Pfizer Inc (NYSE
FE), TIME WARNER INC. (NYSE:TWX), CISCO SYSTEMS INCORPORATED (NASDAQ:CSCO), Medtronic Inc (NYSE:MDT), Depomed Inc (NASDAQ EPO), Powershares Qqq Trust Series 1 (NASDAQ:QQQ). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net . QQQ: 101.40 (+1.38), MDT: 68.16 (+0.73), PFE: 29.95 (+0.11), DEPO: 15.40 (+0.06), CSCO: 24.47 (+0.39), TWX: 79.47 (-0.18)
Depomed Announces Pricing of Upsized $300 Million Convertible Senior Notes Due 2021
PR Newswire - Thu Sep 04, 6:00AM CDT
Depomed, Inc. (Nasdaq: DEPO) today announced that it has priced its registered offering of $300 million aggregate principal amount of Convertible Senior Notes due 2021 (the "Notes"
. The offering was upsized from the previously announced $230 million aggregate principal amount. The Notes will bear interest at a rate of 2.50% per year, payable semiannually on March 1 and September 1 of each year, beginning on March 1, 2015. Depomed, Inc. ("Depomed" has granted the underwriters in the offering a 30-day option to purchase up to an additional $45 million aggregate principal amount of the Notes. Morgan Stanley & Co. LLC and RBC Capital Markets, LLC are acting as joint book-running managers for the offering. The sale of the Notes is expected to close on September 9, 2014, subject to customary closing conditions. DEPO: 15.40 (+0.06), MS: 34.95 (+0.43)
Depomed Set to Possibly Rebound After Yesterday's Selloff of 8.62%
Comtex SmarTrend(R) - Wed Sep 03, 5:45PM CDT
Depomed (NASDAQ
EPO) traded in a range yesterday that spanned from a low of $13.77 to a high of $14.90. Yesterday, the shares fell 8.6%, which took the trading range below the 3-day low of $15.07 on volume of 4.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. DEPO: 15.40 (+0.06)
Nasdaq stocks posting largest percentage decreases
AP - Wed Sep 03, 5:14PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
HELE: 61.85 (+1.09), RESN: 6.00 (unch), DHRM: 4.53 (-0.18), PACB: 6.56 (-0.06), PHII: 42.82 (-0.18), CONN: 31.11 (-0.67), RPRX: 6.34 (-0.41), DEPO: 15.40 (+0.06), PHIIK: 44.74 (+0.22), HMSY: 23.23 (+0.84), SVA: 5.29 (-0.15), DGLY: 14.62 (-0.07)
Depomed Announces Offering of $230 Million Convertible Senior Notes Due 2021
PR Newswire - Tue Sep 02, 3:00PM CDT
Depomed, Inc. (Nasdaq: DEPO) today announced that it intends to offer, subject to market and other conditions, $230 million aggregate principal amount of Convertible Senior Notes due 2021 (the "Notes"
. Depomed, Inc. ("Depomed" expects to grant the underwriters in the offering a 30-day option to purchase up to an additional $34.5 million aggregate principal amount of the Notes. Morgan Stanley & Co. LLC and RBC Capital Markets, LLC will act as joint book-running managers for the offering. Depomed intends to use the net proceeds of the offering for working capital and other general corporate purposes and potential acquisitions and strategic transactions. There are currently no agreements or understandings with respect to any such acquisition or strategic transaction. DEPO: 15.40 (+0.06), MS: 34.95 (+0.43)
(0)
(0)Assertio Therapeutics, Inc. (ASRT) Stock Research Links
Scroll down for more posts ▼